MarketWatch

FDA approves HERNEXEOS(R), the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

The MarketWatch News Department was not involved in the creation of this content. This press release is not intended for UK media -- HERNEXEOS(R) (zongertinib tablets) approved based on an objective ...
The American Journal of Managed Care

Racial Disparities Persist in Curative Treatment for Early-Stage NSCLC Among Medicare Beneficiaries

SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
News Medical

Study helps identify optimal treatment option for NSCLC patients with brain metastases

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to ...
The American Journal of Managed Care

The Evolving Role of Subcutaneous Therapies in EGFR+ NSCLC

EGFR mutations significantly influence NSCLC treatment, with osimertinib showing superior PFS over first-generation TKIs, but resistance remains a challenge. Combination therapies, such as osimertinib ...
Medscape

Thoracic Reirradiation: ‘Attractive’ Option in Recurrent NSCLC

In patients with recurrent non–small cell lung cancer (NSCLC), salvage thoracic reirradiation prolonged overall survival and progression-free survival. Consolidative immunotherapy following ...
Healthline

Non-small Cell Lung Cancer

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Targeted Oncology

Aglatimagene Besadenovec Shows Durable Survival in ICI-Refractory NSCLC

The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
EurekAlert!

New horizons in NSCLC targeted therapy: advancements and challenges

Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...
Zacks Investment Research on MSN

Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...
Business Insider

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

HERNEXEOS ® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial 1 Accelerated approval follows Breakthrough Therapy ...

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

HERNEXEOS product image Product image This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) ...

Boehringer Ingelheim Limited: FDA approves HERNEXEOS, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...